MedTrace Logo

ObsErvational Study of the Practical Cinical UTility of the NuQ.® H3.1 Nucleosome Levels in Adult Patients With Sepsis to Facilitate Early Diagnosis and Prognostication. (EPICETUS)

NCT05922371 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 500

Last updated 2024-04-03

No results posted yet for this study

Summary

This is a study to evaluate the diagnostic performance of the investigation NuQ. (R) H3.1 nucleosome assay as a diagnostic marker of sepsis in a population of patients admitted to critical care with signs suspicious of infection and consistent with the sepsis 3 definition. These patients will be compared to a group of adult surgical patients free from infection that are undergoing their first cardiac surgery.

Conditions

Interventions

DIAGNOSTIC_TEST

NuQ H3.1 Nucleosome Assay

Serial analysis on whole blood of nucleosome levels until resolution of sepsis or discharge.

Sponsors & Collaborators

  • Volition Diagnostics UK Ltd

    collaborator UNKNOWN

  • Guy's and St Thomas' NHS Foundation Trust

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-12-18
Primary Completion
2025-02-01
Completion
2025-03-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05922371 on ClinicalTrials.gov